morfin long 10 mg comprimate cu eliberare prelungită
uzina de preparate endocrine din moscova, ifsu - morfina - comprimate cu eliberare prelungită - 10 mg
morfin long 30 mg comprimate cu eliberare prelungită
uzina de preparate endocrine din moscova, ifsu - morfina - comprimate cu eliberare prelungită - 30 mg
morfin long 60 mg comprimate cu eliberare prelungită
uzina de preparate endocrine din moscova, ifsu - morfina - comprimate cu eliberare prelungită - 60 mg
morfin long 100 mg comprimate cu eliberare prelungită
uzina de preparate endocrine din moscova, ifsu - morfina - comprimate cu eliberare prelungită - 100 mg
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - alte preparate cardiace - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresoare - consultați documentul cu informații despre produs.
sandimmun neoral solutie orala 100 mg/ml
novartis pharma ag - cyclosporinum - solutie orala - 100 mg/ml
mitomicina medac 1mg/ml
medac gesellschaft fÜr klinische spezialprÄparate - germania - mitomicinum - pulb. pt. sol. inj./perf. sau sol. intravezicala - 1mg/ml - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice
iloprost zentiva 10 micrograme/ml
zentiva, k.s - republica ceha - iloprostum - sol. de inhalat prin nebulizator - 10micrograme/ml - antitrombotice antiagregante plachetare
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.